Brief: Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter For Gavreto® (Pralsetinib)
24/10/2024 23:30
Oct 24 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL PHARMACEUTICALS ISSUES DEAR HEALTHCARE PROVIDER
LETTER FOR
GAVRETO® (PRALSETINIB)
Source text for Eikon: ID:nPn6nnFKLa
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)